# Data Sheet (Cat.No.T39463)

TargetMol

## Asundexian

### Chemical Properties



CAS No. : 2064121-65-7

Formula: C26H21ClF4N6O4

Molecular Weight: 592.93

Storage: Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

### Biological Description

| | |
|---|---|
| Description | Asundexian (BAY-2433334) is a potent and orally active inhibitor of the coagulation factor FXIa that directly and reversibly binds to the active site of FXIa, thereby inhibiting its activity.Asundexian has an IC50 of 1 nM for human FXIa in buffer.Asundexian has antitumor activity and may be useful in studies of Acute ischemic stroke, transient ischemic attack and ischemic stroke. |
| Targets(IC50) | Factor Xa |
| In vivo | Asundexian displays potent anticoagulant activity in vitro in human and rabbit plasma and antithrombotic efficacy in vivo in a rabbit arterial thrombosis model.[1] |

### Solubility Information

| | |
|---|---|
| Solubility | DMSO: 150 mg/mL (252.98 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+90% Corn oil: < 10 mg/mL (16.87 mM),Lower concentrations may be soluble, but exact solubility limit is unknown.<br>10% DMSO+90% Saline: < 10 mg/mL (16.87 mM),Lower concentrations may be soluble, but exact solubility limit is unknown.<br>10% DMSO+90% (20% SBE-β-CD in Saline): < 10 mg/mL (16.87 mM),Lower concentrations may be soluble, but exact solubility limit is unknown.<br>10% DMSO+40% PEG300+5% Tween 80+45% Saline: < 10 mg/mL (16.87 mM),Lower concentrations may be soluble, but exact solubility limit is unknown.<br>*Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.* |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 1.6865 mL | 8.4327 mL | 16.8654 mL |
| 5 mM | 0.3373 mL | 1.6865 mL | 3.3731 mL |
| 10 mM | 0.1687 mL | 0.8433 mL | 1.6865 mL |
| 50 mM | 0.0337 mL | 0.1687 mL | 0.3373 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Thomas D, et al. First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa. J Thromb Haemost. 2021;19(10):2407-2416.